Citations

Clear

2303 citation(s) found for "Yu, Edward".

Prevalence of Eustachian Tube Dysfunction in the US Elderly Population
Riley, Charles A. , Hsieh, Mei‐Chin , Marino, Michael J. , Fischer, Jakob L. , Wu, Xiao‐Cheng , McCoul, Edward D.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 23, 2020 | Volume: 163 | Issue: 6 | Pages: 1169-1177

10.1177/0194599820932541 | PMID 32573346 Get It

Objective To investigate the prevalence of eustachian tube dysfunction (ETD) in elderly adults in the United States and its association with other upper aerodigestive inflammatory processes. Study Design Cross‐sectional study. Setting Population based. Subjects and Methods In total, 147,805 patients without malignancy were compared to 13,804 demographically matched patients with malignancy of the upper aerodigestive tract (UADT) by querying the Surveillance, Epidemiology, and End Results (SEER)–Medicare linked database for patients aged 66 to 99 years between 2003 and 2011. The prevalence of ETD and inflammatory diseases among these patients was compared. Association between ETD, other upper aerodigestive inflammatory processes, and UADT malignancies was evaluated. Results The prevalence of ETD was 5.44% among patients without malignancy and 9.08% in those with cancer (odds ratio [OR], 1.73; 95% CI, 1.63‐1.84). Patients with ETD in the control population were more likely (OR, 95% CI) to be diagnosed with chronic rhinitis (5.00, 4.70‐5.33), chronic sinusitis (4.20, 3.98‐4.43), allergic rhinitis (4.27, 4.08‐4.47), and gastroesophageal reflux disease (GERD) (2.42, 2.31‐2.53). Patients with ETD and chronic rhinitis (1.43, 1.24‐1.65), chronic sinusitis (1.57, 1.38‐1.78), and acute otitis media (1.33, 1.08‐1.65) were associated with higher rates of UADT malignancy. Conclusion Over 5% of patients older than 65 in the United States are diagnosed with ETD in the absence of UADT malignancy. Associations between ETD and chronic rhinitis, chronic sinusitis, allergic rhinitis, and GERD in the absence of UADT malignancy suggest that some patients may benefit from treatment of inflammatory disease as a cause of ETD.
Association of Perceived Electronic Health Record Usability With Patient Interactions and Work-Life Integration Among US Physicians
Melnick, Edward R. , Sinsky, Christine A. , Trockel, Mickey , Nedelec, Laurence, Shanafelt, Tait D. , Dyrbye, Liselotte N. , Shanafelt, Tait D , Melnick, Edward R , West, Colin P.

Mayo Clinic

JAMA Network Open | June 22, 2020 | Volume: 3 | Issue: 6 | Pages: e207374

10.1001/jamanetworkopen.2020.7374 | PMID 32568397 Get It

Conditional Survival-Based “Abbreviated” Routine Cancer Surveillance for Pathologic Stage IB Melanoma
Kukar, Moshim , May, Rebecca M., Lichtenthal, Michelle, Groman, Adrienne , Skitzki, Joseph J. , Francescutti, Valerie , Kane, John M. , Gabriel, Emmanuel , Cho, Edward

Mayo Clinic

The American Surgeon™ | June 17, 2020 | Volume: 83 | Issue: 11 | Pages: 1256-1262

10.1177/000313481708301128 Get It

A negative sentinel lymph node biopsy (SLNB) for stage IB (T1b/T2a N0) melanoma would predict an excellent long-term prognosis. Combined with the concept of conditional survival, an “abbreviated” cancer surveillance strategy was implemented to reduce the number of visits and total length of follow-up. Retrospective review of all pathologic stage IB melanoma patients (negative SLNB) at a single institution between 2006 and 2008 after implementation of an “abbreviated” cancer surveillance; clinic visits every six months for five years followed by one annual visit (total follow-up six years). Patient demographics, tumor characteristics, and information regarding recurrences were obtained. Recurrence-free, disease-specific, and overall survival were calculated. Eighty-seven patients underwent the “abbreviated” cancer surveillance. Median age was 55.4 years and 50.6 per cent were male. Median Breslow thickness was 1.1 mm (range 0.5–2.0 mm) and 1.1 per cent were ulcerated. Primary tumor site was 49 per cent extremities, 39 per cent trunk, and 12 per cent head/ neck. Median follow-up was 68.6 months. Five-year recurrence-free, disease-specific, and overall survivals were 89, 95, and 88 per cent, respectively. During surveillance, 10 patients had concerning symptoms or physical findings prompting subsequent workup, all of which were negative for recurrence/metastases. There were only three true melanoma recurrences; all were distant metastases and presented symptomatically between scheduled follow-up visits. In light of the excellent prognosis for pathologic (SLNB negative) stage IB melanoma, an “abbreviated” cancer surveillance schedule based on conditional survival would reduce both direct and indirect costs in this cohort. The few recurrences were symptomatic and unlikely to have changed with more intensive surveillance.
Student‐Led Courses to Teach Cone Beam CT in the Predoctoral Dental Curriculum
Han, James Choon Boon, Garcia, Edward, Huang, John , Angin, Linda L., Han, James, Le, Michael Huan , Miller, Arthur J.

Mayo Clinic

Journal of Dental Education | June 12, 2020 | Volume: 75 | Issue: 9 | Pages: 1176-1186

10.1002/j.0022-0337.2011.75.9.tb05161.x Get It

Cone beam computed tomography (CBCT) provides a new method to evaluate the craniofacial region. The goal of our project was to introduce into the predoctoral dental curriculum a student‐initiated, student‐led introduction to CBCT and how to use it, with minimal expenditure of financial resources. A third‐year student worked with two faculty members to design a course in which a small number of third‐year students would lead a small group of second‐year students. The first approach involved each small group of second‐year dental students discussing one clinical case in which the patient's CBCT record was included. Representatives of each of the ten small groups presented the patient and that patient's clinical problem (e.g., an impacted tooth) to the entire class as well as demonstrating the superiority and limitations of using CBCT in clinical dentistry. The second approach also used small‐group meetings led by third‐year dental students, but paired two second‐year dental students as a team to present the patient's CBCT data in the small‐group setting. There were five teams each presenting a different type of patient as assessed only from the CBCT data. The first model focused on the problem (e.g., an impacted tooth), while the second model focused on how to evaluate and use CBCT scans to determine the patient's primary problem. Based on surveys conducted at the end of each course, the majority of students felt they had gained a better understanding of CBCT.
A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy
Bruining, David H. , Faubion, William A. , Kane, Sunanda V. , Papadakis, Konstantinos A. , Pardi, Darrell S. , Raffals, Laura E. , Schroeder, Kenneth W., Tremaine, William J., Fruth, Kristin M. , Harmsen, William S. , Loftus, Edward V. , Fruth, Kristin, Loftus, Edward V , Coelho–Prabhu, Nayantara , Kisiel, John B.

Mayo Clinic

Inflammatory Bowel Diseases | June 12, 2020 | Volume: 27 | Issue: 5 | Pages: 594-602

10.1093/ibd/izaa146 | PMID 32529198 Get It

Abstract Background We sought to compare the dysplasia detection rate of high-definition white light endoscopy (HDWLE) with that of chromoendoscopy in patients with long-standing inflammatory bowel disease (IBD). Methods This is a retrospective observational cohort of patients with IBD who underwent surveillance colonoscopy between October 1, 2016 and September 30, 2017. We assessed the association between dysplasia detection and multiple variables. Results A total of 808 unique colonoscopies were performed, of which 150 (18.6%) included chromoendoscopy. Primary sclerosing cholangitis was a comorbid diagnosis in 24.5% of patients. The performing endoscopist was an IBD specialist with 37.1% of patients and had >10 years’ experience with 64.9% of patients. Prior dysplasia had been seen in 245 (30.3%) patients: 102 (68.0%) and 143 (22.0%) among patients who had chromoendoscopy and HDWLE, respectively. Dysplasia in polyps was found in 129 procedures (15.1%). Among patients who had chromoendoscopy and HDWLE, polypoid dysplasia was identified in 50 (33.0%) and 79 (12.0%) patients, respectively, P < 0.01. Dysplasia in random biopsies was found in 39 patients (4.8%): 15 (10%) who had chromoendoscopy and 24 (3.6%) who had HDWLE (P < 0.001). On multivariate analysis, patient and disease characteristics significantly associated with an increased odds for polypoid dysplasia included older age at diagnosis (odds ratio [OR] = 1.3 per 10 years; 95% confidence interval [CI], 1.07-1.60), having an IBD physician endoscopist (OR = 1.6; 95% CI, 1.01-2.67), having an endoscopist with less than 10 years’ experience (OR = 1.8; 95% CI (1.16-2.89), and prior random dysplasia (OR = 4.2; 95% CI (1.93-9.17). Concomitant primary sclerosing cholangitis was significantly associated with random dysplasia (OR = 2.3; 95% CI, 1.02-5.07). After multivariate analysis adjusting for these variables, chromoendoscopy was no more likely to identify dysplasia than was HDWLE. Conclusions Chromoendoscopy and HDWLE had a similar diagnostic yield for dysplasia detection in patients with chronic IBD-colitis after adjusting for multiple known risk factors.
Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic
Reinisch, Walter, Danese, Silvio , Peyrin‐Biroulet, Laurent , Loftus, Edward V. , Loftus, Edward V , Danese, Silvio , Peyrin-Biroulet, Laurent

Mayo Clinic

Journal of Crohn's and Colitis | June 5, 2020 | Volume: 14 | Issue: Supplement_3 | Pages: S815-S819

10.1093/ecco-jcc/jjaa119 | PMID 32520311 Get It

Abstract The severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]-causing coronavirus disease [COVID]-19 pandemic poses major challenges for patients with inflammatory bowel disease [IBD] to be recruited and maintained in clinical trials. However, clinical trials offer patients who have failed multiple drugs access to study medications with alternative modes of action and the potential for relief from inflammation-mediated symptoms. Therefore, the continuation of clinical trials in IBD during the COVID-19 pandemic is important both for participants and for the community of IBD patients, due to the dire need for an expanded therapeutic armamentarium. As the safety of patients in clinical trials is the leading principle, we are providing ten specific rules to guide patients and principal investigators safely through the challenging time.
The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance)
Cheng, En , Zhang, Sui , Ou, Fang‐Shu , Mullen, Brian C, Ng, Kimmie , Niedzwiecki, Donna , Mowat, Rex B., Whittom, Renaud , Hantel, Alexander, Benson, Al B. , Atienza, Daniel, Messino, Michael J., Kindler, Hedy L. , Giovannucci, Edward L. , Blarigan, Erin L. Van , Meyerhardt, Jeffrey A. , Fuchs, Charles S. , Mullen, Brian, Saltz, Leonard , Whittom, Renaud , Van Blarigan, Erin L , Meyerhardt, Jeffrey A , Ou, Fang-Shu , Niedzwiecki, Donna , Saltz, Leonard B. , Mayer, Robert J. , Cheng, En

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 4, 2020 | Volume: 29 | Issue: 8 | Pages: 1692-1695

10.1158/1055-9965.epi-19-1454 | PMID 32499312 Get It

Abstract Background: Hyperinsulinemia is considered to be important in the development of colon cancer, but few studies have investigated the associations of hyperinsulinemia with colon cancer survival via dietary scores. Methods: Empirical dietary index for hyperinsulinemia (EDIH) was derived to assess the insulinemic potential of daily diets reflecting the long-term insulin exposure, with higher (more positive) scores indicating higher insulinemic diets. We prospectively estimated the HRs and 95% confidence intervals (CI) to investigate the association of EDIH with disease-free, recurrence-free, and overall survival among patients with stage III colon cancer (1999–2009) enrolled in a randomized adjuvant chemotherapy trial (CALGB 89803). Results: Of 1,024 patients (median follow-up: 7.3 years), 311 died, 350 had recurrences, and 394 had events for disease-free survival. Compared with patients in the lowest quintile of EDIH, the corresponding HRs of patients in the highest quintile for disease-free survival events, cancer recurrence, and overall mortality were 0.80 (95% CI, 0.56–1.15), 0.76 (95% CI, 0.51–1.11), and 0.77 (95% CI, 0.52–1.14). Conclusions: Higher EDIH was not associated with the risk of colon cancer recurrence or mortality in this population of patients with stage III colon cancer. Impact: EDIH, as a measure of dietary insulinemic potential, may be associated with colon cancer risk but not survival in patients with late-stage colon cancer.
Carcinoid Tumors of the Orbit and Ocular Adnexa
Mustak, Hamzah , Liu, Wenjing , Murta, Fabíola, Ozgur, Omar, Couch, Steven M., Garrity, James, Shinder, Roman, Kazim, Michael, Callahan, Alison B. , Hayek, Brent , Esmaeli, Bita , Rootman, Daniel B. , Kim, Hee‐Joon , Yu, Fei , Rose, Geoffrey Edward

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | June 3, 2020 | Volume: 37 | Issue: 3 | Pages: 217-225

10.1097/iop.0000000000001715 | PMID 32496392 Get It

Purpose: Well-differentiated neuroendocrine or carcinoid tumors are found most commonly in the gastrointestinal tract. When metastatic to the orbit, they tend to have a propensity for the extraocular muscles. The purpose of this study was to better understand the diversity in presentation of orbital carcinoid disease and to determine predictors for survival. Methods: In this observational cross-sectional cohort study, data from 8 tertiary orbital practices were compiled. Demographic, clinical, pathologic, American Joint Committee on Cancer stage and grade, imaging, and management data were extracted for all the patients. Descriptive statistics were calculated. Subgroups were compared utilizing analysis of variance analyses and Kaplan–Meier curves. Time to progression and disease-specific and overall mortality were calculated. Comparisons were performed for the following a priori pairs: unknown versus known primary tumor, single versus multiple extraocular muscle involvement, unilateral versus bilateral orbital disease, extraocular muscle versus other orbital involvement, and excisional versus incisional surgery. Results: A total of 28 patients with carcinoid tumors of the orbit were identified. Of these, 57.1% of patients were female, the mean age at diagnosis of the primary tumor was 58.8 years and the mean age at diagnosis of orbital disease was 62.6 years. At primary presentation, all patients were American Joint Committee on Cancer stage III or IV and 21.4% demonstrated carcinoid syndrome. Muscle involvement was noted in 78.6% of patients, and of these, 72% were noted to have single muscle disease. Eight patients had no primary tumor identified; 3 of these 8 demonstrated disseminated disease at the time of diagnosis. The overall 5-year survival rate was 81.8% from diagnosis of primary tumor and 50% from diagnosis of orbital disease. Subgroup analysis revealed that patients with unilateral orbital disease when compared with bilateral orbital disease had a longer progression-free survival and time to death from all causes ( p = 0.025). Patients with disease localized to the orbit at presentation had longer time to death than those with disseminated disease. Treatment with surgery, radiation, or octreotide did not appear to affect survival. Patients managed with systemic chemotherapy had a shorter time of survival than the rest of the group. All other subgroup comparisons were not found to be statistically significant. Conclusions: Neuroendocrine tumors of the orbit represent a wide spectrum of disease, with some cases being part of disseminated disease, while others being localized presentations. This heterogeneity may be responsible for the slightly higher overall survival in these patients than others with metastatic carcinoid tumors in other locations.
Risk of Iodine Deficiency in Extremely Low Gestational Age Newborns on Parenteral Nutrition
Kanike, Neelakanta , Groh‐Wargo, Sharon , Chien, Edward K. , Mhanna, Maroun J. , Kumar, Deepak , Shekhawat, Prem , Shekhawat, Prem S , Thomas, Megan R , Worley, Sarah E. , Singh, Ravinder J.

Mayo Clinic

Nutrients | June 2, 2020 | Volume: 12 | Issue: 6 | Pages: 1636

10.3390/nu12061636 | PMID 32492945 Get It

Iodine is an essential component of thyroid hormones, which play a critical role in neurodevelopment. The iodine status of pregnant women and their newborns is not checked routinely. Extremely Low Gestational Age Newborns do not receive Iodine supplementation while on parenteral nutrition (PN). We measured urine iodine levels and thyroid function tests in 50 mother–infant dyads at birth, at 1 week, 1, 2, 3 months and near discharge. We correlated maternal and neonatal urine iodine levels with thyroid functions and measured iodine levels in milk and PN. In our study, 64% of mothers were iodine deficient at the time of delivery, their free T4 levels were 0.48 (0.41–0.54) ng/dL with normal thyroid-stimulating hormone (TSH). Iodine levels were thirty-fold higher in extremely low gestational age newborns (ELGAN) exposed to iodine comparing to full terms (p < 0.001), but this effect lasted <1 week. At 1 month of age, ELGAN on PN developed iodine deficiency (p = 0.017) and had high thyroglobulin levels of 187 (156–271) ng/mL. Iodine levels improved with enteral feeds by 2 months of age (p = 0.01). Iodine deficiency is prevalent among pregnant women and ELGAN; in particular, those on PN are at risk of hypothyroidism. Iodine supplementation during pregnancy and postnatally should be considered to avoid iodine deficiency.